Doxorubicin-Triggered Immunogenic Cell Death Induces Caspase-1 Pyroptosis and Inflammatory Gasdermin Signaling Cascades

Explore how Doxorubicin triggers immunogenic cell death via Topoisomerase II poisoning, NLRP3 inflammasome nucleation, and Caspase-1/GSDMD pyroptotic lysis.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Doxorubicin couples nuclear Topoisomerase IIα poisoning to mitochondrial redox cycling, generating mitochondrial reactive oxygen species that prime the NLRP3 sensor [1][2].
  • 2
    Stress-induced potassium efflux drives NLRP3 oligomerization and ASC speck assembly, resulting in auto-proteolytic cleavage of pro-caspase-1 into active p20 and p10 catalytic fragments [1][2][3].
  • 3
    Active caspase-1 selectively cleaves Gasdermin D at Asp275 to liberate the 31-kDa N-terminal domain, forming 18-nm transmembrane pores that cause pyroptotic cell swelling and lysis [1][3].
  • 4
    Pyroptotic membrane rupture coordinates the secretion of mature IL-1β and IL-18 alongside classic immunogenic cell death damage-associated molecular patterns, including ATP, HMGB1, and surface calreticulin [4][5].
  • 5
    Bifunctional lytic death markedly enhances cross-priming by conventional type I dendritic cells and recruits CD8+ cytotoxic T lymphocytes into the tumor microenvironment [4][6][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS DOXORUBICIN PATHWAY CASCADE P=Phospho | ->=Activate | -|=Inhibit Doxorubicin IC50 4.8 nM K+ Channel K+ GSDMD Pore Complex I ROS NLRP3 P ASC Caspase-1 GSDMD-NT IL-1β / IL-18 TOP2A γ-H2AX P NF-κB
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin).

A detailed cellular signaling pathway schematic depicting a tumor cell across extracellular, membrane, cytoplasmic, and nuclear compartments. Within the nucleus, Doxorubicin inhibits Topoisomerase IIα and induces DNA double-strand breaks (γ-H2AX). In the mitochondria, redox cycling produces mitochondrial ROS, leading to oxidized mtDNA leak. In the cytoplasm, K+ efflux activates the NLRP3-ASC-Caspase-1 complex, resulting in catalytic p20/p10 cleavage. Active caspase-1 cleaves GSDMD into GSDMD-NT (31 kDa), which forms oligomeric transmembrane pores on the plasma membrane, driving water influx, lytic swelling, and the simultaneous co-release of mature IL-1β, IL-18, ATP, HMGB1, and surface calreticulin exposure.

Topoisomerase II Poisoning and Mitochondrial ROS Coupling to Inflammasome Priming

Doxorubicin functions through intercalation into planar genomic base pairs and stabilization of Topoisomerase II-DNA cleavage complexes, impeding religation and inducing double-strand DNA breaks marked by Ser139 phosphorylated histone γ-H2AX [1][2]. Parallel to nuclear genotoxicity, the anthracycline quinone moiety undergoes single-electron reduction via mitochondrial Complex I and NAD(P)H dehydrogenases [1][3]. Subsequent oxidation of the unstable semiquinone radical generates continuous cascades of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂), promoting mitochondrial outer membrane permeabilization [1]. The resultant loss of inner mitochondrial transmembrane potential leads to cytosolic extrusion of oxidized mitochondrial DNA (mtDNA) and purine catabolites [1][2]. Cytosolic mtDNA engages sensor machineries that stimulate NF-κB transcription, directing the transcriptional synthesis of resting pro-IL-1β, pro-IL-18, and the sensor protein NLRP3 [1][3].

To rigorously benchmark these cellular effects against alternate chemotherapeutic classes, comparative pharmacology profiles are established across standard cytotoxicity, radical generation, and death modalities as outlined in Table 1.

Empirical investigations in human leukemia THP-1 and breast adenocarcinoma MDA-MB-231 models show that doxorubicin-induced reactive oxygen species (ROS) disrupt antioxidant defenses, inactivating Sirt1 and downregulating thioredoxin systems [1][3]. This continuous oxidative tension induces post-translational modifications of NLRP3, comprising dephosphorylation at Ser295 and targeted deubiquitination [1]. These modifications license the sensor for macromolecular assembly. Consequently, Topoisomerase II poisoning acts synergistically with electron transport chain uncoupling, transforming homeostatic cancer cells into immunogenically primed substrates primed for lytic programmed cell death cascades [2][3].

NLRP3-ASC Macromolecular Nucleation and Canonical Caspase-1 Activation

The initiation of canonical pyroptosis requires the assembly of the tripartite NLRP3 inflammasome complex, governed by intracellular ionic perturbations [1][2]. Doxorubicin treatment compromises plasma membrane integrity and alters membrane transport channels, provoking rapid intracellular potassium (K+) efflux [1]. Intracellular K+ drop below the threshold of 90 mM relieves allosteric inhibition across the NLRP3 NACHT domain, exposing its central nucleotide-binding and oligomerization domain [1][2]. In the presence of dATP, NLRP3 undergoes self-oligomerization into an active wheel-like heptameric ring, orienting its pyrin domains (PYD) outward [2].

Exposed PYD motifs nucleate the polymerization of the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) via homotypic PYD-PYD interactions [1][2]. Fluorescent biosensor platforms, such as CASPorter assays engineered in HEK-293 reporter systems, demonstrate that doxorubicin initiates rapid nucleocytoplasmic redistribution of ASC into dense, micron-scale perinuclear ASC specks [2]. Pharmacological inhibition using the NLRP3 blocker MCC950 or the caspase-1 inhibitor VX-765 dose-dependently impedes this oligomerization cascade [2].

Once assembled, filamentous ASC filaments present clustered caspase recruitment domains (CARD) that interface directly with the N-terminal CARD of pro-caspase-1 [1][2]. This homotypic CARD-CARD condensation enforces high-density pro-caspase-1 proximity, driving catalytic homodimerization [1][2]. The clustered zymogens undergo auto-proteolytic processing across two defined interdomain linker sites: cleavage at Asp297 releases the catalytic p20 subunit, while secondary cleavage at Asp316 separates the p10 regulatory subunit from the prodomain [1][2]. The resulting heterotetrameric p20-p10 complex constitutes the enzymatically active caspase-1 protease, prepared to cleave downstream inflammatory substrates and execute membrane permeabilization [1][3].

Gasdermin D Proteolysis, Membrane Insertion, and Pyroptotic Pore Assembly

Following catalytic assembly, active caspase-1 targets the executioner gasdermin family, primarily Gasdermin D (GSDMD) [1][3]. Under resting conditions, GSDMD exists in an auto-inhibited state where its C-terminal repressor domain (GSDMD-CT) sterically masks the lethal N-terminal functional domain (GSDMD-NT) [1]. Caspase-1 executes specific proteolytic cleavage within the central interdomain linker at residue Asp275, liberating the 31-kDa GSDMD-NT executioner fragment from its 22-kDa inhibitory C-terminal partner [1][3]. Uncoupled GSDMD-NT exhibits exposed basic patches that display stereospecific affinity for negatively charged phospholipids restricted to the inner plasma membrane leaflet, specifically phosphatidylserine and phosphoinositides [1].

Upon electrostatically docking to the inner leaflet, GSDMD-NT inserts a four-stranded β-hairpin into the lipid bilayer, initiating conformational changes that direct higher-order ring oligomerization [1][3]. Between 16 and 24 GSDMD-NT protomers coalesce into a hollow, symmetrical transmembrane conduit featuring an inner pore diameter of approximately 10 to 18 nm [1]. This hydrophilic pore breaches cellular ionic selectivity, dissipating transmembrane electrical potentials and permitting unconstrained bi-directional trafficking of ions, water, and osmotic solutes below 15 to 20 kDa in mass [1].

Driven by intracellular oncotic pressure, massive water influx produces rapid cellular swelling characterized by balloon-like, spherical phase-lucent bubbles [1]. Unlike the membrane blebbing and apoptotic vesicle generation driven by actomyosin contractility during apoptosis, pyroptotic tumefaction concludes in physical membrane tearing and complete lytic collapse [1][4]. Quantification in murine C1498 myeloid cells and primary patient-derived blasts reveals that GSDMD pore formation initiates profound lactate dehydrogenase (LDH) release within 12 to 24 hours of exposure [4][5]. This lytic collapse exposes intracellular components directly to the extracellular environment [1][5].

Bifunctional DAMP Emission: Convergence of Canonical ICD with IL-1β and IL-18 Secretion

The catastrophic disruption of the plasma membrane by GSDMD channels establishes a dual immunogenic secretome, integrating active cytokine release with danger-associated molecular pattern (DAMP) extrusion [1][4]. Concurrently with GSDMD cleavage, catalytic caspase-1 processes cytosolic pro-IL-1β and pro-IL-18 at specific aspartate cleavage residues, generating mature, bioactive 17-kDa IL-1β and 18-kDa IL-18 cytokines [1][3]. Because these mature cytokines lack classic endoplasmic reticulum-Golgi secretory leader sequences, they rely on the dilated conduit of GSDMD pores for passive release into the interstitial tumor microenvironment [1][4].

Simultaneously, anthracycline-induced endoplasmic reticulum stress promotes the translocation of the chaperone calreticulin (CRT) to the outer cell membrane, presenting an early "eat-me" signal for phagocytic internalization [5][6]. As the plasma membrane ruptures under osmotic swelling, high-mobility group box 1 (HMGB1) translocates from chromatin to the extracellular space, while intracellular ATP rapidly discharges through open pores [4][5]. Extracellular ATP acts via purinergic P2RX7 receptors to recruit inflammatory phagocytes, whereas HMGB1 ligates Toll-like receptor 4 (TLR4) on local immune populations [4][5].

Murine models utilizing B16F10 melanoma and breast carcinoma show that this simultaneous release of inflammatory cytokines and DAMPs converts immunologically cold microenvironments into highly active hubs [4][7]. Infiltrating conventional type I dendritic cells (cDC1), identified by CD103+ and XCR1+ surface phenotypes, take up tumor antigens and undergo maturation through IL-1β-driven licensing [4][5]. These mature cDC1s traffic efficiently to draining lymph nodes and drive robust cross-presentation to naïve CD8+ T cells [4]. Furthermore, doxorubicin elevates tertiary lymphoid structure (TLS) formation, marked by peripheral node addressin-positive high endothelial venules (PNAd+ HEV) [7]. The resulting effector cytotoxic CD8+ T cells demonstrate elevated tumor infiltration and sustained cytotoxic interferon-gamma production, producing protective systemic antitumor immunity [4][6][7].

Cross-Regulation Between Apoptotic Caspase-3/8 Cascades and Gasdermin Processing

The therapeutic outcome of doxorubicin administration is dictated by an intricate balance between classic apoptotic execution and lytic pyroptosis [4][8]. Exposure to escalating anthracycline concentrations reveals a concentration-dependent threshold where cell fate bifurcates between apoptotic caspase-3/8 cascades and caspase-1-driven pyroptosis [8]. When the apoptotic program predominates, activated caspase-3 cleaves full-length GSDMD at residue Asp87 within its functional N-terminal domain [8]. This secondary processing releases an inactive 13-kDa fragment, dismantling the pore-forming capacity of GSDMD and serving as a molecular damper on pyroptotic lysis [8].

Conversely, tumor cells exhibiting low or mutated Caspase-1/GSDMD expression frequently channel doxorubicin-induced stress toward Gasdermin E (GSDME, also known as DFNA5) [8]. Activated caspase-3 directly hydrolyzes GSDME at Asp270, liberating a 34-kDa GSDME N-terminal fragment (GSDME-NT) [8]. Similar to GSDMD, GSDME-NT oligomerizes in the plasma membrane to assemble lytic pores, executing secondary pyroptosis [8]. In MCF-7 breast cancer cells and multiple myeloma models, doxorubicin promotes both apoptotic marker expression and GSDME-mediated membrane perforation, proving that death pathways can operate cooperatively [3][8].

Modulation of survival proteins further modifies this crosstalk. Doxorubicin treatment diminishes levels of c-FLIP and Mcl-1 in triple-negative BT-549 cells, enhancing susceptibility to extrinsic death signals and perforin-dependent lysis [9]. In addition, while doxorubicin stimulates robust cytotoxic T-cell recruitment, prolonged inflammatory signaling induces adaptive immune resistance by upregulating PD-L1 on non-leukocytic tumor cells and PD-1 on CD8+ T cells [7]. Consequently, combination approaches coupling liposomal doxorubicin with immune checkpoint blockers such as anti-PD-1 or anti-CTLA-4 reverse T-cell exhaustion and prevent tumor recurrence [6][7]. Interrogating the balance between apoptotic silencing and pyroptotic amplification remains essential to optimizing anthracycline immunogenicity without triggering off-target inflammatory toxicities [1][4][8].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Pharmacological Parameter / Biological ReadoutDoxorubicin (Adriamycin)Etoposide (VP-16)Paclitaxel (Taxol)Biological Significance in Pyroptotic Priming
Primary Molecular Target & Binding AffinityTopoisomerase IIα (Kd = 2.4 μM; DNA intercalation)Topoisomerase IIα (Kd = 12.0 μM; non-intercalating)β-Tubulin (Kd = 100 nM; microtubule stabilization)Dual planar intercalation and catalytic pocket trapping drive sustained genotoxic stress.
Antiproliferative Potency (IC50 in Solid Tumors)40 - 250 nM (breast, sarcoma, lymphoma)1.2 - 5.0 μM (small cell lung, testicular)5 - 20 nM (ovarian, breast, NSCLC)High potency enables sub-micromolar triggers of rapid mitochondrial decoupling.
Mitochondrial ROS Production IndexMarked (quinone-hydroquinone redox cycling)Minimal (negligible electron decoupling)Moderate (secondary organelle stress)Direct quinone redox cycling generates early mtROS essential for NLRP3 sensor priming.
Primary Programmed Cell Death ModalityPyroptosis & Apoptosis (Bifunctional, GSDMD/E)Apoptosis (Caspase-3/9 predominant)Mitotic Catastrophe & Classic ApoptosisDirect activation of caspase-1 and gasdermin pore cleavage induces lytic, inflammatory rupture.
DAMP & Inflammatory Secretome ProfileHigh (CRT, HMGB1, ATP, mature IL-1β, IL-18)Moderate (ATP, HMGB1; minimal cytokines)Moderate (CRT exposure; negligible IL-1β)Co-release of gasdermin-dependent cytokines and classic DAMPs licenses cDC1 antigen cross-presentation.

Note: All comparative parameters compiled from standardized in vitro antiproliferative assays, live-cell kinetic biosensors, and secretome quantification across standardized mammalian tumor models.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

How can researchers experimentally distinguish between caspase-1-driven pyroptosis and caspase-3-mediated apoptosis following Doxorubicin exposure?Experimental Model Selection

To differentiate these death pathways, investigators should deploy kinetic dual-staining live-cell imaging combining cell-impermeable DNA fluorophores (such as Sytox Green or propidium iodide) with Annexin V [1][4]. Pyroptosis is defined by rapid plasma membrane perforation and dye uptake preceding or coinciding with phosphatidylserine externalization, accompanied by substantial early lactate dehydrogenase (LDH) release and spherical ballooning [1][4]. Apoptosis exhibits prolonged Annexin V single-positivity with intact membrane exclusion and membrane blebbing [4]. Western blotting should assess the presence of the active caspase-1 p20/p10 subunits and the 31-kDa GSDMD-NT fragment, alongside pharmacological rescue using the specific caspase-1 inhibitor VX-765 or the NLRP3 antagonist MCC950 [1][2][8].

What cell culture conditions are essential to minimize artifactual readings when evaluating Doxorubicin-induced inflammasome activation?In Vitro Assay Protocol Optimization

Because doxorubicin possesses intrinsic fluorescence (excitation ~480 nm, emission ~590 nm), experiments quantifying cell viability, ROS, or dye uptake must utilize phenol red-free media and appropriate spectral compensation [1][2]. Furthermore, to observe canonical NLRP3 inflammasome priming and subsequent caspase-1 cleavage, extracellular potassium levels must be maintained strictly below physiological cellular levels to allow necessary potassium efflux [1][2]. When performing biosensor-based measurements (such as CASPorter assays) or measuring IL-1β/IL-18 via ELISA, serum lot consistency and absence of exogenous endotoxin contaminants are vital to avoid background TLR4 priming prior to anthracycline introduction [2][5].

Why is GSDMD considered a bifunctional executioner in tumor immunity compared to apoptotic caspases?Mechanistic Pathway Distinction

GSDMD acts bifunctionally because its 18-nm transmembrane pore executes non-tolerogenic, lytic cellular death while simultaneously acting as a transport conduit for mature IL-1β and IL-18 [1][3][4]. In contrast to apoptotic caspases, which activate downstream nucleases (CAD) and condense cellular components into silent apoptotic bodies, caspase-1-mediated GSDMD cleavage causes rapid osmotic lysis and discharges high concentrations of intact ATP and HMGB1 alongside calreticulin exposure [4][5]. This inflammatory secretome specifically activates CD103+ and XCR1+ conventional type I dendritic cells, triggering efficient antigen cross-presentation and functional CD8+ T-cell expansion within the tumor microenvironment [4][6].

References

  1. [1]. Shi S, et al. Cell Communication and Signaling. 2023;21(1).
  2. [2]. Zou C, et al. Journal of Inflammation Research. 2022;Volume 15:1183-1194. [IF: 4.5]
  3. [3]. Laxita S, et al. Diseases & Research. 2025;5(1):19-36.
  4. [4]. Inkol JM, et al. Journal for ImmunoTherapy of Cancer. 2024;12(4):e006781. [IF: 10.6]
  5. [5]. Liu Y, et al. Journal for ImmunoTherapy of Cancer. 2025;13(7):e011148. [IF: 10.6]
  6. [7]. Aimohammadi R, et al. International Journal of Nanomedicine. 2020;Volume 15:5279-5288. [IF: 6.4]
  7. [6]. Zhao H, et al. Frontiers in Immunology. 2024;15. [IF: 5.9]
  8. [8]. Wang H, et al. Frontiers in Oncology. 2022;12. [IF: 4.7]
  9. [9]. Inao T, et al. Cancer Science. 2019;110(9):2690-2699. [IF: 4.966]